Log in

Adalta Stock Price, News & Analysis (ASX:1AD)

Today's Range N/A
50-Day Range
A$0.11
MA: A$0.17
A$0.22
52-Week Range N/A
Volume45,658 shs
Average VolumeN/A
Market Capitalization$17.76 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
AdAlta Limited, a drug discovery and development company, develops protein therapeutics. The company focuses on developing its lead i-body drug candidate, AD-114, for the treatment of idiopathic pulmonary fibrosis and other fibrotic diseases. It has a collaborative partnership with Excellerate Bioscience to advance the development of its i-body pipeline. AdAlta Limited was incorporated in 2006 and is based in Bundoora, Australia.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone61 3 9479 5159

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.54 million
Book ValueA$0.05 per share

Profitability

Miscellaneous

EmployeesN/A
Market Cap$17.76 million
Next Earnings DateN/A
OptionableNot Optionable

Receive 1AD News and Ratings via Email

Sign-up to receive the latest news and ratings for 1AD and its competitors with MarketBeat's FREE daily newsletter.


Adalta (ASX:1AD) Frequently Asked Questions

What is Adalta's stock symbol?

Adalta trades on the ASX under the ticker symbol "1AD."

Has Adalta been receiving favorable news coverage?

News articles about 1AD stock have trended somewhat positive recently, according to InfoTrie Sentiment. The research firm identifies positive and negative press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Adalta earned a media sentiment score of 0.8 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Adalta.

Who are some of Adalta's key competitors?

Who are Adalta's key executives?

Adalta's management team includes the folowing people:
  • Ms. Samantha Cobb, CEO, MD & Exec. Director
  • Dr. Dallas Hartman, Chief Operating Officer
  • Prof. Michael Foley Ph.D., Chief Scientific Advisor & Chief Scientific Officer
  • Mr. Cameron Jones, Company Sec.

How big of a company is Adalta?

Adalta has a market capitalization of $0.00 and generates $3.54 million in revenue each year. View Additional Information About Adalta.

What is Adalta's official website?

The official website for Adalta is http://www.adalta.com.au/.

How can I contact Adalta?

The company can be reached via phone at 61 3 9479 5159.


MarketBeat Community Rating for Adalta (ASX 1AD)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  5 (Vote Outperform)
Underperform Votes:  4 (Vote Underperform)
Total Votes:  9
MarketBeat's community ratings are surveys of what our community members think about Adalta and other stocks. Vote "Outperform" if you believe 1AD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe 1AD will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/20/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel